Amarin 10-Q Details First Quarterly Profit in Over Two Years and $323.4M Cash Pile
AMRN is trading near its 52-week low of $11.25 (6.2% above the low).
Summary
Amarin's Q3 2026 10-Q confirms a $0.245M net profit — its first in over two years — on 44% lower operating expenses, with $323.4M of cash and no debt even as U.S. VASCEPA revenue fell 30%.
Key Events · Earnings and Guidance · AMRN
-
First Quarterly Profit Since 2024
Q3 2026 net income was $0.245M versus a $7.7M net loss in Q3 2025, as total operating expenses fell 44% to $18.5M from $33.3M.
-
Revenue Still Shrinking
Total revenue fell 20% to $39.6M; U.S. product revenue dropped 30% to $28.5M on lower net selling price from generic competition, partly offset by licensing and royalty revenue up 139% to $2.7M.
-
Cash Build, Zero Debt
Cash, cash equivalents and short-term investments reached $323.4M at September 30, 2026, with $22.2M of operating cash flow over nine months versus $8.5M used in the prior-year period and no debt outstanding.
-
Hikma Litigation Settled
On October 13, 2026 the parties agreed to a confidential settlement dismissing all patent infringement claims with prejudice; Hikma also agreed to dismiss its antitrust claims for a negotiated payment recognized in Q2 2026.
Analysis · AMRN · Life Sciences
Hard numbers behind this morning's earnings release: Q3 2026 net income of $0.245M versus a $7.7M loss a year ago, driven by operating expenses falling 44% to $18.5M after the completed European restructuring. Revenue still shrank 20% to $39.6M as U.S. VASCEPA sales dropped 30% to $28.5M on lower net pricing from generic competition, so profitability rests on cost cuts, not growth. The balance sheet is the real story — $323.4M of cash and short-term investments, no debt, and $22.2M of operating cash flow generated over nine months versus a $8.5M burn last year. The filing also confirms the Hikma patent case was settled and dismissed with prejudice on October 13, 2026, and that the six antitrust class actions were settled and dismissed in April 2026, removing a large legal overhang. With the core U.S. franchise still eroding, the value case now hinges on what Barclays' strategic review produces.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRN was trading at $11.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $252.4M. The 52-week trading range was $11.25 to $20.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.